Sequential surgery, radiation therapy, and alkeran in the management of epithelial carcinoma of the ovary

✍ Scribed by Roger Potish; Leon Adcock; Doris Brooker; Thomas K. Jones Jr.; Seymour H. Levitt; Takashi Okagaki; Konald Prem

• Publisher: John Wiley and Sons
• Year: 1980
• Tongue: English
• Weight: 418 KB
• Volume: 45
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19800601)45:11<2754::aid-cncr2820451109>3.0.co;2-q

✦ Synopsis

In 1970, a prospective multidisciplinary protocol was initiated for Stages I through III obviously malignant ovarian epithelial carcinomas. The planned sequential therapy included 1) surgery, 2) radiotherapy (2000 rads to whole abdomen, 3000 rad boost to pelvis), 3) chemotherapy (ten cycles of Alkeran), and 4) a "second-look" surgical procedure. Ninety-six patients were enrolled in this program through 1976. Median follow-up of the survivors was greater than 44 months. Adjusted disease-free survival was 90 percent for Stage 1,64 percent for Stages IIB-IIC, and 16 percent for Stage 111. Stage 111 patients with no palpable tumor at time of initiation of radiation therapy had a survival of 37 percent. No Stage I11 patient with palpable tumor at time of initiation of radiation therapy was cured. Eight percent of patients developed small bowel obstruction requiring surgical intervention. Three percent of all patients died of hematologic causes; of the 30-month-plus survivors, 5 percent (2 of 37) developed acute myelogenous leukemia. Cure and toxicity will be examined in detail and compared with the literature.